Today: September 29, 2016, 8:43 pm

By 2017, Genentech and Regeneron are expected to split the AMD, DME, and RVO segments with their VEGF inhibitors Lucentis and Eylea
US Retinal Therapeutics Market reports more than 15 compounds in phase 2 development or beyond - a new market research report on 2014-03-19 00:33:03
The US Retinal Therapeutics Market reports there are more than 15 compounds in Phase 2 development and beyond. If approved, Allergan will have the first once-every-3-months VEGF inhibitor with AGN-150998, expected to launch in 2018 to 2019. If Phase 3 data shows comparable efficacy and safety to current VEGF inhibitors, Allergan has the potential to gain market share due to its less frequent dosing.

Ophthotec´s platelet-derived growth factor (PDGF) inhibitor Fovista has the potential to become the first add-on therapy to VEGF inhibitors. This product has significant market potential due to a complementary rather than competitive add-on therapy strategy. New treatments that can be administered orally or topical drops would revolutionize treatment; however, it appears unlikely that any current pipeline medications will have comparable safety and efficacy profiles to current VEGF treatments.

Since the introduction of Lucentis in 2006, vascular endothelial growth factor (VEGF) antagonists have become the clear choice in treatment for age related macular degeneration, diabetic macular edema, and retinal vein occlusion due to their high efficacy and safety.

By 2017, Genentech and Regeneron are expected to split the AMD, DME, and RVO segments with their VEGF inhibitors Lucentis and Eylea, respectively. Eylea´s favorable bi-monthly dosing has enabled Regeneron to be a viable competitor to Genentech´s Lucentis. In 2014, Eylea´s label will expand to include DME.

Eylea and Lucentis are comparably priced; however, Avastin is available through compounding pharmacies at an immense discount, which significantly disrupts the branded AMD, DME, and RVO market. Although new VEGF treatments are highly efficacious, they require intravitreal injections which is an invasive procedure. Thus, dosing frequency is a key determinant of market uptake.

The AMD, DME, and RVO segments are set for continued growth due to an aging US population, and the DME segment in particular due to an increasing prevalence of diabetes.

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Press Information

Published by
Mike King
London: +44 (0) 203 086 8600

# 517 Words
Related Articles
More From Finance
P2P lending platform Monexo partners with IDBI-Trusteeship [..]
For Immediate Release: 2nd September 2016 MUKESH BUBNA, CEO Monexo Fintech Pvt Limited P2P [..]
Day Trade to Win New September Class [..]
Sold Out? New Class Added – On September 6, 2016, is launching a brand new eight-week trading boot camp [..]
FTM (Forget The Market) Reopens 3 Shares [..]
Port Vila, Vanuatu, 28th July 2016 - Investment firm FTM today announced the reopening of three separate share options, projected [..]
Ex-Citibanker Launching Online P2P marketplace in India [..]
A study conducted by World Bank shows that MSMEs in India face an estimated credit gap of INR 20.9 trillion [..]
New Frontier Portfolios Top Morningstar Rankings
New Frontier’s global strategic portfolios topped the Global Balanced Strategic/All-Inclusive category of the latest Morningstar ETF [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.